FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2133244310> ?p ?o ?g. }

• W2133244310 endingPage "1419" @default.
• W2133244310 startingPage "1409" @default.
• W2133244310 abstract "Diabet. Med. 27, 1409–1419 (2010) Abstract Aims The efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, linagliptin, added to ongoing metformin therapy, were assessed in patients with Type 2 diabetes who had inadequate glycaemic control (HbA 1c ≥ 7.5 to ≤ 10%; ≥58.5 to ≤85.8 mmol/mol) with metformin alone. Methods Patients ( n = 333) were randomized to receive double‐blind linagliptin (1, 5 or 10 mg once daily) or placebo or open‐label glimepiride (1–3 mg once daily). The primary outcome measure was the change from baseline in HbA 1c at week 12 in patients receiving combination therapy compared with metformin alone. Results Twelve weeks of treatment resulted in a mean ( sem ) placebo‐corrected lowering in HbA 1c levels of 0.40% (± 0.14); 4.4 mmol/mol (± 1.5) for 1 mg linagliptin, 0.73% (± 0.14); 8.0 mmol/mol (± 1.5) for 5 mg, and 0.67% (± 0.14); 7.3 mmol/mol (± 1.5) for 10 mg. Differences between linagliptin and placebo were statistically significant for all doses (1 mg, P = 0.01; 5 mg and 10 mg, P < 0.0001). The change in mean ( sem ) placebo‐corrected HbA 1c from baseline was −0.90% (± 0.13); −9.8 mmol/mol (± 1.4) for glimepiride. Adjusted and placebo‐corrected mean changes in fasting plasma glucose were −1.1 mmol/l for linagliptin 1 mg ( P = 0.002), −1.9 mmol/l for 5 mg and −1.6 mmol/l for 10 mg (both P < 0.0001). One hundred and six (43.1%) patients reported adverse events; the incidence was similar across all five groups. There were no hypoglycaemic events for linagliptin or placebo, whereas three patients (5%) receiving glimepiride experienced hypoglycaemia. Conclusions The addition of linagliptin to ongoing metformin treatment in patients with Type 2 diabetes was well tolerated and resulted in significant and clinically relevant improvements in glycaemic control, with 5 mg linagliptin being the most effective dose." @default.
• W2133244310 created "2016-06-24" @default.
• W2133244310 creator A5007041822 @default.
• W2133244310 creator A5021947247 @default.
• W2133244310 creator A5023372650 @default.
• W2133244310 creator A5044778195 @default.
• W2133244310 creator A5050453842 @default.
• W2133244310 creator A5056064349 @default.
• W2133244310 creator A5066453545 @default.
• W2133244310 creator A5068995047 @default.
• W2133244310 date "2010-11-09" @default.
• W2133244310 modified "2023-10-17" @default.
• W2133244310 title "Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes" @default.
• W2133244310 cites W1913239326 @default.
• W2133244310 cites W1971414511 @default.
• W2133244310 cites W1999488408 @default.
• W2133244310 cites W2003207506 @default.
• W2133244310 cites W2011238752 @default.
• W2133244310 cites W2022501381 @default.
• W2133244310 cites W2027593203 @default.
• W2133244310 cites W2028648326 @default.
• W2133244310 cites W2034574623 @default.
• W2133244310 cites W2037026646 @default.
• W2133244310 cites W2042129134 @default.
• W2133244310 cites W2048565142 @default.
• W2133244310 cites W2055384431 @default.
• W2133244310 cites W2069150029 @default.
• W2133244310 cites W2074511950 @default.
• W2133244310 cites W2087707716 @default.
• W2133244310 cites W2101246901 @default.
• W2133244310 cites W2102643655 @default.
• W2133244310 cites W2108771199 @default.
• W2133244310 cites W2114542756 @default.
• W2133244310 cites W2115176755 @default.
• W2133244310 cites W2118186702 @default.
• W2133244310 cites W2123946536 @default.
• W2133244310 cites W2128766821 @default.
• W2133244310 cites W2152969995 @default.
• W2133244310 cites W2153449155 @default.
• W2133244310 cites W2163251867 @default.
• W2133244310 cites W2171667655 @default.
• W2133244310 cites W2322400090 @default.
• W2133244310 cites W2324992560 @default.
• W2133244310 cites W4245367233 @default.
• W2133244310 doi "https://doi.org/10.1111/j.1464-5491.2010.03131.x" @default.
• W2133244310 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21059094" @default.
• W2133244310 hasPublicationYear "2010" @default.
• W2133244310 type Work @default.
• W2133244310 sameAs 2133244310 @default.
• W2133244310 citedByCount "116" @default.
• W2133244310 countsByYear W21332443102012 @default.
• W2133244310 countsByYear W21332443102013 @default.
• W2133244310 countsByYear W21332443102014 @default.
• W2133244310 countsByYear W21332443102015 @default.
• W2133244310 countsByYear W21332443102016 @default.
• W2133244310 countsByYear W21332443102017 @default.
• W2133244310 countsByYear W21332443102018 @default.
• W2133244310 countsByYear W21332443102019 @default.
• W2133244310 countsByYear W21332443102020 @default.
• W2133244310 countsByYear W21332443102022 @default.
• W2133244310 countsByYear W21332443102023 @default.
• W2133244310 crossrefType "journal-article" @default.
• W2133244310 hasAuthorship W2133244310A5007041822 @default.
• W2133244310 hasAuthorship W2133244310A5021947247 @default.
• W2133244310 hasAuthorship W2133244310A5023372650 @default.
• W2133244310 hasAuthorship W2133244310A5044778195 @default.
• W2133244310 hasAuthorship W2133244310A5050453842 @default.
• W2133244310 hasAuthorship W2133244310A5056064349 @default.
• W2133244310 hasAuthorship W2133244310A5066453545 @default.
• W2133244310 hasAuthorship W2133244310A5068995047 @default.
• W2133244310 hasConcept C126322002 @default.
• W2133244310 hasConcept C126894567 @default.
• W2133244310 hasConcept C134018914 @default.
• W2133244310 hasConcept C142724271 @default.
• W2133244310 hasConcept C204787440 @default.
• W2133244310 hasConcept C27081682 @default.
• W2133244310 hasConcept C2776307423 @default.
• W2133244310 hasConcept C2777180221 @default.
• W2133244310 hasConcept C2778763485 @default.
• W2133244310 hasConcept C2780031085 @default.
• W2133244310 hasConcept C2780323712 @default.
• W2133244310 hasConcept C555293320 @default.
• W2133244310 hasConcept C71924100 @default.
• W2133244310 hasConcept C90924648 @default.
• W2133244310 hasConcept C98274493 @default.
• W2133244310 hasConceptScore W2133244310C126322002 @default.
• W2133244310 hasConceptScore W2133244310C126894567 @default.
• W2133244310 hasConceptScore W2133244310C134018914 @default.
• W2133244310 hasConceptScore W2133244310C142724271 @default.
• W2133244310 hasConceptScore W2133244310C204787440 @default.
• W2133244310 hasConceptScore W2133244310C27081682 @default.
• W2133244310 hasConceptScore W2133244310C2776307423 @default.
• W2133244310 hasConceptScore W2133244310C2777180221 @default.
• W2133244310 hasConceptScore W2133244310C2778763485 @default.
• W2133244310 hasConceptScore W2133244310C2780031085 @default.
• W2133244310 hasConceptScore W2133244310C2780323712 @default.
• W2133244310 hasConceptScore W2133244310C555293320 @default.
• W2133244310 hasConceptScore W2133244310C71924100 @default.

• next